AMBER SENATOR: Open Payments
NPI 1558863597 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,756 in 61 payments from 17 companies in 2025. Trend: 2023 $2,449 · 2024 $3,588 · 2025 $1,756
Food & beverage: $1,756
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 15 | $468 |
| ABBVIE INC. | 14 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $179 |
| Mallinckrodt Hospital Products Inc. | 1 | $145 |
| AstraZeneca Pharmaceuticals LP | 1 | $127 |
| GENZYME CORPORATION | 1 | $119 |
| Madrigal Pharmaceuticals | 3 | $100 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $59 |
| Gilead Sciences, Inc. | 3 | $58 |
| PFIZER INC. | 3 | $55 |
Products named: TREMFYA, TERLIVAZ, DUPIXENT, DATROWAY, MAVYRET, REZDIFFRA, XELJANZ, IQIRVO.
Industry payments across AZ — which companies pay providers there.
